The Effect of LHRH Antagonist Cetrorelix in Crossover Conditioned Media from Epithelial (BPH-1) and Stromal (WPMY-1) Prostate Cells

Hormone and Metabolic Research

Volumn 46, Issue 1, 2014, Pages 21-26

  Siejka, A ^a,b,c,d   Schally, A V ^a,b,c   Barabutis, N ^a,b,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b South Florida Veterans Affairs Foundation for Research and Education   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

benign prostatic hyperplasia; BPH 1; Cetrorelix; LHRH antagonist; LHRH receptor; WPMY 1

Indexed keywords

CETRORELIX; CYCLINE; GONADORELIN ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; STAT3 PROTEIN;

ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; STROMA CELL;

CELL LINE; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE; RECEPTORS, LHRH; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892538260     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0033-1349127     Document Type: Article

References (41)

1. Price H., McNeal J. E., Stamey T. A. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol: 1990; 21 578 585
2. Starsichova A., Lincova E., Pernicova Z., Kozubik A., Soucek K. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell Signal: 2010; 22 1734 1744
3. Schauer I. G., Rowley D. R. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation: 2011; 82 200 210
4. Barabutis N., Catravas J. D. Anti-Inflammatory Activity of Hsp90 Inhibitors in the Human Vasculature. Med Surg Urol: 2013; 2 e104
5. Alonso-Magdalena P., Brossner C., Reiner A., Cheng G., Sugiyama N., Warner M., Gustafsson J. A. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA: 2009; 106 2859 2863
6. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol: 2012; 19 10 17
7. Schally A. V. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res: 2008; 40 315 322
8. Siejka A., Schally A. V., Block N. L., Barabutis N. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int: 2010; 106 1382 1388
9. Li W., Wu C. L., Febbo P. G., Olumi A. F. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol: 2007; 171 1189 1198
10. Webber M. M., Trakul N., Thraves P. S., Bello-DeOcampo D., Chu W. W., Storto P. D., Huard T. K., Rhim J. S., Williams D. E. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis: 1999; 20 1185 1192
11. Palapattu G. S., Sutcliffe S., Bastian P. J., Platz E. A., De Marzo A. M., Isaacs W. B., Nelson W. G. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis: 2005; 26 1170 1181
12. De Marzo A. M., Platz E. A., Sutcliffe S., Xu J., Gronberg H., Drake C. G., Nakai Y., Isaacs W. B., Nelson W. G. Inflammation in prostate carcinogenesis. Nat Rev Cancer: 2007; 7 256 269
13. Hayward S. W., Dahiya R., Cunha G. R., Bartek J., Deshpande N., Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim: 1995; 31 14 24
14. Bajusz S., Csernus V. J., Janaky T., Bokser L., Fekete M., Schally A. V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res: 1988; 32 425 435
15. Barabutis N., Schally A. V. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer: 2008; 98 1790 1796
16. Barabutis N., Siejka A., Schally A. V., Block N. L., Cai R., Varga J. L. Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. J Mol Endocrinol: 2010; 44 127 134
17. Siejka A., Lawnicka H., Komorowski J., Schally A. V., Stepień T., Krupiński R., Stepień H. GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. Life Sci: 2003; 72 2473 2479
18. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol: 2004; 6 S3 S10
19. Roehrborn C. G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int: 2008; 101 17 21
20. Auffenberg G. B., Helfand B. T., McVary K. T. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am: 2009; 36 443 459 v-vi
21. Siejka A., Schally A. V., Block N. L., Barabutis N. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate: 2010; 70 1087 1093
22. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle: 2009; 8 1168 1175
23. Kyriakis J. M., Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev: 2012; 92 689 737
24. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer: 2009; 9 798 809
25. Barabutis N., Schally A. V. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle: 2010; 9 4110 4116
26. Huang H. F., Murphy T. F., Shu P., Barton A. B., Barton B. E. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer: 2005; 4 2
27. Moldovan G. L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell: 2007; 129 665 679
28. Wang W., Bergh A., Damber J. E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate: 2004; 61 60 72
29. Shimizu I., Yoshida Y., Katsuno T., Tateno K., Okada S., Moriya J., Yokoyama M., Nojima A., Ito T., Zechner R., Komuro I., Kobayashi Y., Minamino T. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab: 2012; 15 51 64
30. Schlechte H., Lenk S. V., Loning T., Schnorr D., Rudolph B. D., Ditscherlein G., Loening S. A. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur Urol: 1998; 34 433 440
31. Addadi Y., Moskovits N., Granot D., Lozano G., Carmi Y., Apte R. N., Neeman M., Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res: 2010; 70 9650 9658
32. Hill R., Song Y., Cardiff R. D., Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell: 2005; 123 1001 1011
33. Trimis G., Chatzistamou I., Politi K., Kiaris H., Papavassiliou A. G. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum Mol Genet: 2008; 17 3596 3600
34. Rick F. G., Schally A. V., Block N. L., Abi-Chaker A., Krishan A., Szalontay L. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate: 2012; 73 873 883
35. Rick F. G., Schally A. V., Block N. L., Halmos G., Perez R., Fernandez J. B., Vidaurre I., Szalontay L. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate: 2011; 71 736 747
36. Rick F. G., Abi-Chaker A., Szalontay L., Perez R., Jaszberenyi M., Jayakumar A. R., Shamaladevi N., Szepeshazi K., Vidaurre I., Halmos G., Krishan A., Block N. L., Schally A. V. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci USA: 2013; 110 2617 2622
37. Petronilho F., Vuolo F., Galant L. S., Constantino L., Tomasi C. D., Giombelli V. R., de Souza C. T., da silva S., Barbeiro D. F., Soriano F. G., Streck E. L., Ritter C., Zanotto-Filho A., Pasquali M. A., Gelain D. P., Rybarczyk-Filho J. L., Moreira J. C., Block N. L., Roesler R., Schwartsmann G., Schally A. V., Dal-Pizzol F. Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: involvement of toll-like receptor 4 signaling. Mol Med: 2012; 18 1209 1219
38. Lucas R., Sridhar S., Rick F. G., Gorshkov B., Umapathy N. S., Yang G., Oseghale A., Verin A. D., Chakraborty T., Matthay M. A., Zemskov E. A., White R., Block N. L., Schally A. V. Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proc Natl Acad Sci USA: 2012; 109 2084 2089
39. Barabutis N., Schally A. V. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA: 2008; 105 20470 20475
40. Barabutis N., Siejka A., Schally A. V. Growth hormone releasing hormone induces the expression of nitric oxide synthase. J Cell Mol Med: 2011; 15 1148 1155
41. Rick F. G., Szalontay L., Schally A. V., Block N. L., Nadji M., Szepeshazi K., Vidaurre I., Zarandi M., Kovacs M., Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol: 2012; 187 1498 1504